BCIwiki — Brain-computer interface news, research and industry database

Seven Chinese ministries led by MIIT issued guidelines targeting breakthroughs in core BCI technologies by 2027 — including electrodes, chips, and integrated devices at internationally competitive levels — with accelerated deployment in manufacturing, healthcare, and consumer markets. By 2030, the plan calls for cultivating 2–3 globally influential BCI companies and building an internationally competitive industry ecosystem.

A perspective review published in Computers in biology and medicine examines EEG non-stationarity across sessions, people, and recording conditions. It asks whether mechanisms that help the brain maintain functional stability can improve the robustness of brain-computer interface models. The review covers synaptic plasticity, homeostatic regulation, neural oscillations, and spiking representations, comparing bio-inspired approaches with conventional machine learning and transfer learning. It also considers hybrid designs that combine biologically grounded mechanisms with artificial neural networks. The author proposes operational definitions for bio-inspired, bio-plausible, and bio-realistic modeling, together with a minimum specification for continual EEG benchmarks. Because direct EEG evidence remains limited for several proposed mechanisms, the review stresses the need to distinguish empirical findings from hypotheses and future research directions.

The FDA cleared Universal Brain's UB ERP System on June 30, 2026, finding it substantially equivalent under submission number K253767 through the traditional 510(k) pathway. The agency classifies it as Non-Normalizing Quantitative Electroencephalograph Software, a Class II device under regulation 882.1400, with neurology as the assigned review panel. Event-related potentials are obtained by averaging EEG time-locked to stimuli; components such as P300 serve both clinical assessment and the classic paradigms behind noninvasive BCI spellers.

The FDA cleared the Ceribell Monitor on June 30, 2026, finding it substantially equivalent under submission number K261101 through the traditional 510(k) pathway. The agency classifies it as a Reduced-Montage Standard Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. It is one of several Ceribell clearances in the same period; the product line is built around rapid reduced-montage setup for bedside recording in emergency and critical care.

A research team has developed Brain2Qwerty, a deep learning model that decodes sentences people type from non-invasive brain recordings. Thirty-five healthy volunteers typed sentences they had just memorized while their magnetoencephalography (MEG, which measures the brain's magnetic fields) or EEG signals were recorded. The average character error rate was 29% with MEG and 65% with EEG; for the best-performing participants it fell to as low as 18%, and the model fully decoded a range of sentences outside its training set. The researchers say the results narrow the gap between non-invasive and implanted methods.

Researchers propose an injectable, in-situ-gelling multifunctional hydrogel to address the failure modes of micro-ECoG cortical recording — dural barrier disruption, cortical micromotion that weakens device-tissue coupling, and biofouling that triggers a foreign-body response. Combining dopamine-grafted sodium alginate with branched polyethyleneimine, the hydrogel forms a quasi-zwitterionic network that resists nonspecific protein adsorption and provides catechol-mediated wet adhesion, gelling rapidly under surgical-compatible conditions through dual macromolecular crosslinking without diffusible small-molecule monomers. Integrated with a 128-channel flexible micro-ECoG mesh array, the platform reduced glial activation and fibrotic encapsulation and preserved stable, high-fidelity cortical recording over the 3-week early chronic period. The authors say co-designing barrier repair, interface adhesion and antifouling in a single material can improve long-term function.

The FDA approved a premarket approval (PMA) supplement, S039, from Saluda Medical Pty, Ltd. on June 29, 2026, covering the CAP24 Paddle Lead, Passing Elevator, Evoke CLS (REF 3042), Clarity Programming Application (CPA) and RECAP Viewer. The supplement is a labeling change touching indications, instructions for use, shelf life and trade name rather than an original approval of a new device; the products carry the generic name 'stimulator, spinal-cord, totally implanted for pain relief.' Saluda Medical is an Australian company whose Evoke system is one of the few closed-loop spinal cord stimulators on the market.

Researchers transferred dexamethasone-loaded titania nanotube arrays (TNA) onto a mechanically adaptive polymer nanocomposite (NC) substrate and, in a mouse model, compared four implants — silicon, NC, TNA-NC Empty and TNA-NC DEX (10 mice per group) — for neuroinflammation around intracortical microelectrodes at 2 and 4 weeks. At 2 weeks the gene-expression profiles were broadly similar, reflecting an early acute injury response; by 4 weeks the patterns diverged, with NC-based implants showing fewer differentially expressed neuroinflammatory genes than rigid silicon, led by TNA-NC Empty, while the dexamethasone group showed no additional benefit, suggesting drug delivery still needs optimization. The authors conclude that adding a TNA layer to flexible materials promotes resolution of the neuroinflammatory response at 4 weeks.

MVCLDG combines raw EEG and Hilbert-derived phase information with domain-alignment and contrastive-learning constraints to improve classification across unseen users. It outperformed baseline and representative domain-generalization methods on a public error-related-negativity dataset and a semantic-syntactic-violation dataset without target-domain adaptation; ablation and activation-map analyses supported the contribution and neurophysiological plausibility of its components.

Guangdong issued a provincial BCI action plan targeting 100 new tech companies, 200 BCI hospital wards and a ten-billion-yuan industry by 2030.